Medical expert of the article
New publications
Brain cancer vaccine testing shows positive results
Last reviewed: 01.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Celldex Therapeutics, Inc. today announced that its immunotherapy vaccine Rindopepimut has shown positive results in prolonging the survival of patients with newly diagnosed glioblastoma, one of the most aggressive forms of brain cancer, to about 15 months after tumor detection.
Rindopepimut acts on a specific molecule called the tumor epidermal growth factor receptor EGFRvIII. EGFRvIII are mutated forms of the epidermal growth factor receptor (EGFR) that are found only in cancer cells and are transforming oncogenes that promote cancer cell growth.
Detection of EGFRvIII is associated with poor patient survival prognosis, independent of other factors such as the extent of tumor resection during surgery and age.
The results of the vaccine testing showed that the average life expectancy of patients reached 24 months. These data prove that Rindopepimut prolongs the life of patients almost 2 times. Scientists are preparing to begin phase 3 clinical trials of the vaccine.
High levels of immunity in vaccinated patients are associated with loss of EGFRvIII replication capacity. Rindopepimut is generally well tolerated during treatment for up to 7 years; adverse events consisted mainly of injection site reactions, fatigue, skin rash, nausea, and did not exceed 10%.